HCA Healthcare delivered solid results in the second quarter, with revenue and earnings per share both ahead of Wall Street expectations. The positive market reaction reflected management’s ability to navigate significant headwinds, particularly an unexpected increase in uninsured patient volumes following the expiration of enhanced premium tax credits. CEO Samuel N. Hazen highlighted that while overall patient demand remained robust—especially for emergency services—unfavorable payer mix shifts put pressure on margins as more patients migrated from insurance exchanges to uninsured status. Hazen noted, “Adjusted admissions for patients who were formerly covered by the health insurance exchanges declined by 15%,” with nearly all of those patients becoming uninsured.
Is now the time to buy HCA? Find out in our full research report (it’s free for active Edge members).
HCA Healthcare (HCA) Q2 CY2026 Highlights:
- Revenue: $20.23 billion vs analyst estimates of $19.76 billion (8.7% year-on-year growth, 2.4% beat)
- EPS (GAAP): $7.62 vs analyst estimates of $7.46 (2.2% beat)
- Adjusted EBITDA: $4.03 billion vs analyst estimates of $4.00 billion (19.9% margin, 0.6% beat)
- EPS (GAAP) guidance for the full year is $29.60 at the midpoint, missing analyst estimates by 1.2%
- EBITDA guidance for the full year is $15.75 billion at the midpoint, in line with analyst expectations
- Operating Margin: 15.3%, in line with the same quarter last year
- Market Capitalization: $85.69 billion
While we enjoy listening to the management’s commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From HCA Healthcare’s Q2 Earnings Call
- Ben Hendrix (RBC Capital Markets) asked about the variables behind the increased estimate for exchange headwinds and how management’s confidence in those judgments has evolved. CFO Michael A. Marks explained the updated guidance reflects the company’s experience in the first half, specifically that nearly all patients losing exchange coverage became uninsured, which was a bigger driver than initially assumed.
- Albert Rice (UBS) inquired about the drivers behind declines in elective surgeries and whether deferred procedures might rebound later in the year. CEO Samuel N. Hazen attributed most of the softness to affordability challenges and loss of coverage, but noted emergent surgery volumes remained stable, and it remains uncertain if postponed cases will materialize later.
- Ann Hynes (Mizuho Securities) pressed for details on capital allocation and competitive positioning amid changing service mix. Hazen detailed ongoing investments in both inpatient and outpatient capacity, emphasizing stable to growing market share in core geographies and the need for flexibility to respond to local competition.
- Brian Tanquilut (Jefferies) asked about cost trends and the impact of resiliency programs. Marks noted that overall cost per admission was flat year-over-year, with progress in containing professional fees, though anesthesia and radiology costs remain above inflation.
- Kevin Fischbeck (Bank of America) questioned the specific components behind the full-year EBITDA guidance reduction. Marks clarified that moderation in overall growth rates, especially from the payer mix shift, drove the adjustment, bringing guidance closer to HCA’s long-term target range.
Catalysts in Upcoming Quarters
Going forward, our analysts will be monitoring (1) the pace and impact of uninsured volume growth and its effect on payer mix, (2) the realization and durability of cost savings from HCA’s financial resiliency and digital initiatives, and (3) the execution of capacity expansions and demographic-driven demand in high-growth markets. Regulatory developments and further payer mix shifts will also be critical to watch.
HCA Healthcare currently trades at $397.60, up from $376.50 just before the earnings. Is the company at an inflection point that warrants a buy or sell? Find out in our full research report (it’s free).
Our Favorite Stocks Right Now
ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.
Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,552% between June 2020 and June 2025). Find your next big winner with StockStory today.
